TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9713781
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) 0.4 mg/mL for 2 minutes
Study: 9713781
Drug: Control balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control balanced salt solution
Study: 7993985
Drug: Single 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 750 mg oral dose of Vigabatrin (VGB)
Study: 3281387
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine
Study: 29358543
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message reminders about oral hygiene
Study: 19663522
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg/day)
Study: 22103958
Drug: Combination pharmacotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination pharmacotherapy (nicotine patch + nicotine lozenge, bupropion + nicotine lozenge)
Study: 22103958
Drug: Monotherapy (nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (nicotine patch, nicotine lozenge, bupropion)
Study: 11403509
Drug: Combination treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatments
Study: 12967792
Drug: Verteporfin therapy
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin therapy (Visudyne, Novartis AG)
Study: 1734249
Drug: Prophylactic nonabsorbable
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic nonabsorbable antibiotics (tobramycin, colistin sulfate, and amphotericin B) administered through a nasogastric tube
Study: 1734249
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered through a nasogastric tube
Study: 1734249
Drug: Prophylactic nonabsorbable
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic nonabsorbable antibiotics
Study: 30938654
Drug: 4 mini-implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mini-implants
Study: 30938654
Drug: 2 mini-implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mini-implants
Study: 30938654
Drug: 2 standard
Normalized name: Onguard2 Standard 20 mm Vial Adaptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 standard implants
Study: 9383925
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (15 minutes a day for 30 days)
Study: 9383925
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (control group)
Study: 320940
Drug: 1% clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clotrimazole solution
Study: 30078167
Drug: remifentanil +
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil + methadone (MET) (0.1 mg/kg IV over 15 min)
Study: 30078167
Drug: remifentanil +
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil + magnesium (MAG) (50 mg/kg bolus over 30 min followed by 10 mg/kg/h)
Study: 26643501
Drug: CRUSADE score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRUSADE score >40 with 24-month dual antiplatelet therapy
Study: 26643501
Drug: CRUSADE score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRUSADE score ≤40 with 24-month dual antiplatelet therapy
Study: 26643501
Drug: CRUSADE score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRUSADE score >40 with 6-month dual antiplatelet therapy
Study: 18831886
Drug: Risedronate (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (2.5 mg/day) and calcium (900 mg/day)
Study: 18831886
Drug: Calcium (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (900 mg/day) alone
Study: 11268446
Drug: Oral HCFU,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HCFU, 300 mg daily for 52 weeks starting 2 weeks after surgery
Study: 8256242
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (1 mg)
Study: 8256242
Drug: Budesonide (1
Normalized name: budesonide (11.beta.,16.alpha.(S))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (1 mg)
Study: 27219886
Drug: Synbiotic supplements
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplements containing 3 probiotic bacteria (Lactobacillus acidophilus 2×10^9, Lactobacillus casei 2×10^9, Bifidobacterium bifidum 2×10^9 CFU/g) plus 800 mg inulin
Study: 26133741
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (n=45)
Study: 23247052
Drug: Pharmacological weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological weight loss treatment
Study: 18957616
Drug: Insulin with
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin with BQ-123 (type A endothelin receptor antagonist)
Study: 18957616
Drug: Insulin with
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin with BQ-123
Study: 18957616
Drug: Insulin (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (higher dosing in obese subjects)
Study: 1616160
Drug: Physician-controlled administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician-controlled administration of alfentanil
Study: 1616160
Drug: Patient-controlled administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled administration of alfentanil
Study: 15374134
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg paroxetine daily for 42 days
Study: 6799848
Drug: Other drugs
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drugs (not specified)
Study: 2822878
Drug: Minimum effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimum effective dosage of ACE inhibitors
Study: 2822878
Drug: Supine rest,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supine rest, infusion of angiotensin II, atropine, saline
Study: 27314763
Drug: Brief parent‐delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief parent‐delivered treatment for child anxiety
Study: 27314763
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with strategies specifically targeting parental tolerance of their child's negative emotions
Study: 25714521
Drug: Clipping or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clipping or coiling treatment (specifics on dosage and duration not available)
Study: 23225796
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of clopidogrel (aspirin 100 mg + clopidogrel 150 mg daily)
Study: 23225796
Drug: Cilostazol (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (aspirin 100 mg + clopidogrel 75 mg + cilostazol 100 mg bid daily)
Study: 19906658
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (200 mg bimonthly)
Study: 11970744
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 40 mg four times daily (n=403)
Study: 1521670
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg buflomedil given orally twice daily for 90 days
Study: 29972120
Drug: Suspension exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension exercise training in addition to routine rehabilitation training
Study: 26182441
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 4 mg/kg
Study: 20692030
Drug: Pentavalent rotavirus
Normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent rotavirus vaccine (2 mL, three oral doses at 6, 10, and 14 weeks of age)
Study: 20692031
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three oral doses)
Study: 25080553
Drug: Pentavalent rotavirus
Normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent rotavirus vaccine
Study: 9469358
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 20 mg/m2
Study: 9469358
Drug: Bleomycin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin and vincristine (BV) combination
Study: 7637156
Drug: Amrinone infusion
Normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amrinone infusion
Study: 480949
Drug: Diethylstilbestrol (DES)
Normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylstilbestrol (DES) 5 mg orally t.i.d.
Study: 480949
Drug: Diethylstilbestrol (DES)
Normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylstilbestrol (DES) 5 mg orally t.i.d. + Chlorambucil (CB) 0.1‐‐0.2 mg/kg/day orally
Study: 17288611
Drug: Tetracaine 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 4% gel applied to the skin for 30 minutes
Study: 17288611
Drug: Sucrose administration
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose administration (24% sucrose)
Study: 27084728
Drug: Tiotropium Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat 5 μg once daily
Study: 27084728
Drug: Tiotropium HandiHaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium HandiHaler 18 μg once daily
Study: 12685617
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nitrate treatment)
Study: 10099056
Drug: Tiazac (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiazac (240 mg single dose)
Study: 10099056
Drug: Cardizem CD
Normalized name: Cardizem CD
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardizem CD (240 mg single dose)
Study: 2679397
Drug: Allopurinol mouth
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol mouth wash (4-5 times daily before and after treatment)
Study: 31476260
Drug: Percutaneous valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous valve repair plus medical treatment (n=152)
Study: 31476260
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment alone (n=152)
Study: 18365222
Drug: Postoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative administration of 0.1 mg fentanyl + 5 ml bupivacaine 0.5%
Study: 18365222
Drug: Postoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative administration of 5 ml bupivacaine 0.5% alone
Study: 17803345
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 40 mg/day
Study: 15465069
Drug: Psychotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy or antidepressant medications
Study: 11396760
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of tissue adhesive N-butyl-2-cyanoacrylate (group 2, 18 patients)
Study: 9849455
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus filgrastim
Study: 598635
Drug: Isosorbide dinitrate,
Normalized name: isosorbide dinitrate, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide dinitrate, 5 mg sublingually
Study: 598635
Drug: Propranolol, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 40 mg orally
Study: 31402145
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A deficiency (retinol <0.7 μmol/L)
Study: 28870407
Drug: D2/3 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2/3 receptor availability in striatal regions (including bilateral ventral pallidum/nucleus accumbens, right ventral caudate, and putamen)
Study: 28870407
Drug: D2/3 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2/3 receptor availability in the caudal portion of the ventral striatum (NAc/vPAL)
Study: 26251413
Drug: Group cognitive-behavioural
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioural therapy (RAFT) delivered by local rheumatology clinical teams, consisting of 6 sessions of 2 hours each (weeks 1-6) and a 1-hour consolidation session (week 14).
Study: 26251413
Drug: Group cognitive-behavioural
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioural therapy (RAFT).
Study: 16849756
Drug: Window therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Window therapy (various agents including ifosfamide, etoposide, doxorubicin, topoisomerase I poisons)
Study: 16849756
Drug: Ifosfamide/topoisomerase II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide/topoisomerase II inhibitor trials
Study: 16154241
Drug: Aerosol measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol measles vaccine (10(3.58) CCID50/0.1 mL)
Study: 17038828
Drug: Aerosol measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol measles vaccine
Study: 21742842
Drug: Subcutaneous measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous measles vaccine
Study: 31466854
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg with carboplatin and etoposide
Study: 25886645
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) containing anti-JEV neutralizing antibody (ImmunoRel, 400mg/kg/day for 5 days)
Study: 16324780
Drug: 20,000 UI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20,000 UI of lyophilized HAase (5 ml)
Study: 14998735
Drug: Cue-dose training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cue-dose training (n = 16)
Study: 3553874
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine in elderly subjects (70% vaccinated)
Study: 3553874
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine in younger subjects (50% vaccinated)
Study: 3553874
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine in younger subjects
Study: 21773992
Drug: PTH(1-84) 100
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH(1-84) 100 µg daily for 24 weeks
Study: 19435203
Drug: Mixed sorbent
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed sorbent (microcellulose + polysorb) (6g), administered once a week, on average 20 days after operation.
Study: 8270988
Drug: Arm D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm D: E 130 mg/m2 by 24-hour infusion and P 45 mg/m2 by 24-hour infusion on day 2 and 3 only
Study: 2572797
Drug: L-tyrosine (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tyrosine (9 g daily for 4 weeks)
Study: 239966
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose practolol (1.5 mg/kg)
Study: 29885904
Drug: Haloperidol 5
Normalized name: haloperidol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5 mg
Study: 23504930
Drug: Short-term hormone
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term hormone therapy (futamide plus a luteinizing hormone-releasing hormone agonist for 4 months)
Study: 14566568
Drug: Glucose ingested
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose ingested 30 min before exercise (50 g)
Study: 14566568
Drug: Glucose ingested
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose ingested during exercise (110 g or 160 g in fractionated doses)
Study: 14566568
Drug: Glucose ingested
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose ingested both before and during exercise (50 g before and 110 g during)
Study: 8770969
Drug: Sirolimus (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (1 to 3 mg/m2/day)
Study: 8770969
Drug: Sirolimus (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (5 to 6 mg/m2/day)
Study: 8770969
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg/m2/day)
Study: 8770969
Drug: Sirolimus (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (any dose)
Study: 1612040
Drug: Simethicone 65
Normalized name: Simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone 65 mg in 90 ml of water
Study: 1612040
Drug: Simethicone 65
Normalized name: Simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone 65 mg in 30 ml of water
Study: 1612040
Drug: Simethicone 195
Normalized name: Simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone 195 mg in 90 ml of water
Study: 30879470
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation (CR) consisting of 10 therapy sessions over 3 months, followed by four maintenance sessions over 6 months.
Study: 28689852
Drug: Integrated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive behavioral therapy for co-occurring opioid use disorder and anxiety disorders
Study: 28689852
Drug: Active comparison
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparison treatment targeting opioid use disorder alone
Study: 16772353
Drug: Ghrelin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin (10 pmol/kg.min) infusion for 180 min
Study: 10694094
Drug: Specific antiglycolipid
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific antiglycolipid antibodies in serum and circulating immune complexes
Study: 10694094
Drug: IgG antibody
Normalized name: CM1 IgG antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibody levels against glycolipid LOS
Study: 10694094
Drug: IgG antibody
Normalized name: CM1 IgG antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibody against LOS
Study: 10694094
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antigens tested in serum
Study: 10694094
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of immune complexes and IgG antibodies against glycolipid antigens
Study: 3233058
Drug: Amoxicillin 40
Normalized name: amoxicillin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 40 mg.kg‐1 every 12 hours by IV route
Study: 3233058
Drug: Amoxicillin 40
Normalized name: amoxicillin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 40 mg.kg‐1 every 12 hours by oral route
Study: 29247809
Drug: IV diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV diclofenac (two doses of 75mg in the first 24h after diagnosis)
Study: 23791063
Drug: Tulobuterol patch
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol patch
Study: 23791063
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol sulfate
Study: 21612452
Drug: Experimental green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental green tea extract (40 mL, rinsed for 1 minute, three times a day for a week)
Study: 21612452
Drug: Placebo mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouth rinse (40 mL, rinsed for 1 minute, three times a day for a week)
Study: 14535872
Drug: OAC7 (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC7 (omeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d. for 7 days)
Study: 14535872
Drug: OAC14 (clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC14 (clarithromycin 500 mg b.d. for 14 days)
Study: 6425480
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation with total parenteral nutrition (120% of estimated energy requirements, 3.75% or 22.5% as lipid, amino acids 2.5 gm/120 kcal)
Study: 6425480
Drug: Post-parenteral nutrition
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-parenteral nutrition period
Study: 29514712
Drug: Sirukumab 50
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 50 mg q4w
Study: 24699939
Drug: Sirukumab 100
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 100 mg q2w
Study: 24434117
Drug: Creatine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (20 g/d for 7 d)
Study: 16019358
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (CEE) alone
Study: 28001147
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation with 2 g of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032
Study: 26414563
Drug: Caloric titration
Normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caloric titration method (CTM)